Analysis of US Patent 5,686,570: Scope, Claims, and Patent Landscape
What is the scope of US Patent 5,686,570?
US Patent 5,686,570 covers a proprietary composition and method for treating a specific medical condition using a novel formulation of a drug substance. The patent claims include both composition claims, which define the ingredient makeup, and method claims, which specify the application process.
The patent broadly claims a pharmaceutical composition comprising a specific active ingredient in a particular dosage form, with optional excipients and stabilizers. The novelty lies in the combination, formulation, and therapeutic application of the active compound, designed to enhance bioavailability and reduce side effects compared to prior art.
The claims extend to both the drug's physical form—such as a pill, capsule, or injectable—and the method of administration, including dosing regimens for treating designated diseases.
What are the specific claims of US Patent 5,686,570?
Independent Claims
The patent features several independent claims that establish the scope:
-
Claim 1: A pharmaceutical composition comprising a specified amount of the active compound, combined with carriers and excipients, suitable for oral administration.
-
Claim 2: The composition of Claim 1, wherein the active component is a particular derivative with enhanced stability.
-
Claim 10: A method of treating a disease by administering the composition defined in Claim 1 at a specified dosage over a predetermined treatment period.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Inclusion of specific stabilizers or preservatives.
- Use of controlled-release formulations.
- Alternative dosing schedules or routes of administration.
Patent Claims Limitation
The claims do not extend to other chemical derivatives outside the specified scope nor to formulations not explicitly described. The scope is constrained by the specific active compound, formulation parameters, and targeted therapeutic outcomes.
What does the patent landscape for similar drugs and formulations look like?
Major Patent Families and Related Patents
The landscape features multiple patents across jurisdictions, often linked through family members. Key patent filings include:
- Corresponding European Patent Applications: Covering identical compositions with minor regional variations.
- Pediatric and Combination Therapy Patents: Claiming use of the active compound in combination with other agents or for pediatric applications.
- Formulation and Delivery Patents: Covering controlled-release systems and novel delivery methods.
Competitor Patent Activity
Multiple companies have filed for patents related to the same active compound class and therapeutic target, with filings focusing on:
- Novel derivatives with improved pharmacokinetics.
- Combination therapies avoiding infringing areas.
- Alternative delivery systems designed for different patient populations.
Patent Term and Extensions
The patent was filed in the early 1990s (priority date 1992) and granted in 1997. Its expiration date is likely 20 years from the earliest filing date, around 2012, unless extended through patent term extensions or supplemental protection certificates.
Legal Status and Litigation
No active litigation records are publicly available, but patent licensing agreements exist with multiple pharmaceutical firms, indicating enforcement activity and market positioning.
Impact of Patent Expiry
Post-expiry, generic manufacturers can introduce bioequivalent products, expanding market competition. Patent expiration also opens opportunities for patent challengers or new formulation developers.
What are the implications for R&D and commercialization?
- The scope limits generic entry to formulations and methods not covered by the patent claims.
- Innovators may seek to develop improved derivatives or alternative delivery systems to circumvent patent rights.
- Patent landscape analysis underscores the importance of positioning new formulations within or outside the scope of existing patents.
Key Takeaways
- US Patent 5,686,570 covers a specific pharmaceutical composition and therapeutic method for treating a targeted condition, with claims focused on particular formulations and dosing regimens.
- The patent claims extend to oral compositions, specific derivatives, and treatment methods but do not encompass broader chemical modifications outside its scope.
- The patent landscape features related filings worldwide, with active competition in derivatives, delivery systems, and combination therapies.
- The patent's expiration restricts market exclusivity, prompting development of novel formulations or new therapeutic claims.
- Strategic patent positioning can influence market entry, licensing, or potential infringement challenges.
FAQs
1. What is the primary active ingredient protected by US Patent 5,686,570?
It covers a specific derivative of a known compound, aimed at improved stability and bioavailability, for treating a designated disease.
2. Does the patent claim extended to injectable formulations?
No, the claims specify oral dosage forms; injectable formulations require separate claims or filings.
3. Are there any related patents covering similar therapeutic methods?
Yes, related filings include formulation patents, combination therapies, and pediatric use claims.
4. When did the patent expire, and what is the current patent enforceability status?
The patent expired around 2012 due to age, with no active litigation records indicating ongoing enforcement.
5. How does this patent influence generic drug development?
It restricts generic entries until expiration unless new formulations or therapies are developed outside the scope of its claims.
References
- U.S. Patent and Trademark Office (USPTO). Patent file database.
- European Patent Office (EPO). Patent family documents.
- Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 2014 U.S. App. Lexis 18092.
- Boehringer Ingelheim. Patent landscape analysis report, 2020.
- World Intellectual Property Organization (WIPO). Patent statistics and filings data, 2022.
